Display options
Cite
McFarland MS, Huddleston L, Tammareddi K, et al. Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy. J Drug Assess. 2012;1(1):34-9doi: 10.3109/21556660.2012.707996.
McFarland, M. S., Huddleston, L., Tammareddi, K., McKenzie, M., & Bean, J. (2012). Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy. Journal of drug assessment, 1(1), 34-9. https://doi.org/10.3109/21556660.2012.707996
McFarland, M Shawn, et al. "Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy." Journal of drug assessment vol. 1,1 (2012): 34-9. doi: https://doi.org/10.3109/21556660.2012.707996
McFarland MS, Huddleston L, Tammareddi K, McKenzie M, Bean J. Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy. J Drug Assess. 2012 Jun 29;1(1):34-9. doi: 10.3109/21556660.2012.707996. eCollection 2012. PMID: 27536426; PMCID: PMC4980726.
Copy Download .nbib Format: NLM
Share it on

J Drug Assess. 2012 Jun 29;1(1):34-9. doi: 10.3109/21556660.2012.707996. eCollection 2012.

Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy.

Journal of drug assessment

M Shawn McFarland, Lana Huddleston, Kumar Tammareddi, Michael McKenzie, Jennifer Bean

Affiliations

  1. Department of Veterans Affairs - TN Valley Health Care System, Pharmacy Service, Murfreesboro, TN; The University of Tennessee College of Pharmacy, Memphis, TNUSA.
  2. Department of Veterans Affairs - TN Valley Health Care System, Pharmacy Service, Nashville, TNUSA.
  3. Department of Veterans Affairs - TN Valley Healthcare System, Murfreesboro, TNUSA.
  4. The University of Tennessee Department of Clinical Pharmacy, Memphis, TNUSA.
  5. Department of Veterans Affairs - TN Valley Healthcare System, Department of Pharmacy, Murfreesboro, TN; The University of Tennessee Department of Clinical Pharmacy, Memphis, TNUSA.

PMID: 27536426 PMCID: PMC4980726 DOI: 10.3109/21556660.2012.707996

Abstract

OBJECTIVES: It has been proposed that the combination of thiazolidinedione (TZD) therapy to metformin and sulfonylurea is beneficial due to each medication having a unique mechanism of action. Within the Veterans Affairs Hospital, specific criteria of use define when TZD therapy can be initiated. Most patients who receive TZD therapy have failed other medications prior to use. The primary objective of this study was to determine the percentage of patients achieving the American Diabetes Association (ADA) goal hemoglobin A1c (A1c) of less than 7% with the addition of pioglitazone to the maximal/highest tolerated doses of sulfonylurea and metformin combination therapy.

METHODS: This was a six healthcare system retrospective, descriptive, analysis of type 2 diabetic patients (DM-2). Patients must have received the maximal/highest tolerated doses of sulfonylurea and metformin combination therapy and have been TZD naïve or off TZD therapy for a minimum of 6 months, a baseline A1c greater than 7%, a repeat A1c at 3 and 6 months available, and deemed medication compliant.

RESULTS: We evaluated 98 total patients. The percentage of veteran patients achieving ADA goal A1c of less than 7% after the addition of pioglitazone reached statistical significance at both 3 and 6 months post TZD initiation. The mean reduction in A1c post-pioglitazone initiation was 0.67% (SD ± 0.92) and 0.78% (SD ± 0.94) at 3 and 6 months, respectively.

CONCLUSION: The addition of pioglitazone to veteran patients who were already receiving maximal/highest tolerated doses of sulfonylurea was able to achieve a higher percentage in with the ADA goal A1c of less than 7%. Initiating pioglitazone in patients with an A1c of 9% or greater did not reach statistical significance in achieving an A1c less than 7%. The initial starting dose of pioglitazone 30 mg can be considered as compared to 15 mg daily if contraindications do not exist.

Keywords: Hemoglobin A1c; Thiazolidinediones; Type 2 diabetes

References

  1. Lancet. 1998 Sep 12;352(9131):854-65 - PubMed
  2. N Engl J Med. 2009 Jan 8;360(2):129-39 - PubMed
  3. N Engl J Med. 2008 Jun 12;358(24):2545-59 - PubMed
  4. J Am Geriatr Soc. 2003 May;51(5 Suppl Guidelines):S265-80 - PubMed
  5. N Engl J Med. 2008 Jun 12;358(24):2560-72 - PubMed
  6. Am J Med. 2004 Feb 15;116(4):230-5 - PubMed
  7. Diabetes Care. 2009 Jan;32(1):193-203 - PubMed
  8. Diabetes Care. 2010 Jan;33 Suppl 1:S11-61 - PubMed
  9. Diabet Med. 2009 Oct;26(10):1033-9 - PubMed
  10. N Engl J Med. 2006 Dec 7;355(23):2427-43 - PubMed

Publication Types